Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients

Journal of Clinical Oncology

Volumn 23, Issue 19, 2005, Pages 4287-4297

  Dressler, Lynn G ^a   Berry, Donald A ^b   Broadwater, Gloria ^b   Cowan, David ^b   Cox, Kelly ^b   Griffin, Stephanie ^b   Miller, Ashley ^b   Tse, Jessica ^b   Novotny, Debra ^b   Persons, Diane L ^b   Barcos, Maurice ^b   Henderson, I Craig ^b   Liu, Edison T ^b   Thor, Ann ^b   Budman, Dan ^b   Muss, Hy ^b   Norton, Larry ^b   Hayes, Daniel F ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; CAF PROTOCOL; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC KIT; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COMPARATIVE STUDY; EVALUATION; FEMALE; GENE AMPLIFICATION; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 22344451611     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.012     Document Type: Article

References (34)

1. Muss HB, Thor AD, Berry DA, et al: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
2. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
3. Paik S, Bryant JB, Park C, et al: ErbB-2 and response to doxorubicin in patients with axillary lymph node- positive, hormone-receptor negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
4. Clark GM: Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 90:1320-1321, 1998
5. Ravdin PM, Green S, Albain KS, et al: Initial report of the SWOG biological correlative study of c-erbB2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc Am Soc Clin Oncol 17:97, 1998 (abstr)
6. Ravdin PM: Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 26:117-123, 1999 (suppl 12)
7. Cobleigh MA, Vogel CL, Tripathy D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr)
8. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpression metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
9. Dressler L, Thor AD: HER2 Testing: Laboratory, Technical and Clinical Considerations. Breast Disease 11:77-87, 2000
10. Lal P, Slalzar PA, Hudis CA, et al: HER2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual color and single color scoring. Am J Clin Pathol 121:631-636, 2004
11. Ginistier C, Charaffe-Jauffret E, Penault-Llora F, et al: Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 202:286-298, 2004
12. Press MF, Slamon DJ, Park J, et al: Evaluation of HER2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:4607-4609, 2002
13. van de Vijver M: Emerging technologies for HER2 testing. Oncology 63:33-38, 2002 (suppl)
14. CAP, College of Amer Pathol: Cell Markers and Cytogenesis Committees: Clinical laboratory assays for HER2/neu amplification and overexpression: Quality assurance, standardizatin and proficiency testing. Arch Pathol Lab Med 126:803-808, 2002
15. Mass RD, Sanders C, Charlene K, et al: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 19:75a, 2002 (abstr)
16. Wood, WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl J Med 330:1253-1259, 1994 [erratum in N Engl J Med 331:139, 1994]
17. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
18. Kute TE, Quadri Y, Muss H, et al: Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B Protocol 8869. Cytometry 11:297-306, 1995
19. Persons D, Bui MM, Yung J-F, et al: Fluorescence in-situ hybridization (FISH) for detection of HER-2/neu amplifiation in breast cancer: A multicenter portability study. Ann Clin Lab Sci 30:41-48, 2000
20. Masood S, Bui MM, Yung J-F: Reproducibility of LSI Her2/neu Spectrum Orange and CEP 17 Spectrum Green dual color deoxyribonucleic acid probe kit. Ann Clin Lab Sci 28:215-223, 1998
21. Liu E, Thor A, Mei H, et al: The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027-1031, 1992
22. Neubauer A, Naubauer B, Mei H, et al: Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 7:1019-1025, 1992
23. Agresti A: A Categorical Data Analysis. New York, NY, Wiley Interscience, 1990, pp 365-370
24. Cox D: Regression modesl and life tables (with discussion). J Royal Stat Soc B 34:187-220, 1972
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Amer Stat Assoc 53:457-481, 1958
26. Slamon D, Leyland-Jones B, Shak S, et al: Addition of HERCEPTIN (humanized antiHER2 antibody) to first line chemotherapy for HER2 overexpressing metastastic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phasee II trial. Proc Amer Soc Clin Oncol 17:98, 1998 (abstr)
27. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti p185 HER-2 monoclonal antibody in patient the HER-2/neu overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
28. Konecny G, Fritz M, Untch M, et al: HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res Treat 69:53-63, 2001
29. Petit T, Borel C, Ghnassia JP, et al: Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 7:1577-1581, 2001
30. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
31. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
32. Press M, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
33. Cowan D, Dressier LG: Simultaneous evaluation of erbB2 protein expression and gene amplification: A sequential double label technique combining immunohistochemistry and fluorescence in situ hybridization. Breast Cancer Res Treat 50:2945, 1998 (abstr 375)
34. Jacobs TW, Gown AW, Allen W, et al: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974-1982, 1999